<DOC>
	<DOCNO>NCT02553473</DOCNO>
	<brief_summary>Comparison Doxycycline 200 mg daily six week versus Doxycycline 200 mg daily two week + placebo four week . Primary objective answer question `` two week doxycycline treatment ( currently suggest treatment ) least effective six week doxycycline treatment Lyme Neuroborreliosis ? `` .Key secondary objective provide good understanding pathogenesis long‐term complaint , search new biomarkers Lyme Neuroborreliosis ( LNB ) collect clinical data , blood , cerebrospinal fluid ( CSF ) biobank future research Endpoints : Primary endpoint : Composite clinical score six month end treatment.Secondary endpoint : Fatigue Severity Scale ( FSS ) , Patient Health Questionnaire ( PHQ-15 ) , Short Form 36 ( SF-36 ) blood CSF finding inclusion , 6 12 month . The study design multicenter , non-inferiority , randomize , penta-blind , placebo-controlled trial . 250 patient include Sørlandet Hospital 5-10 Norwegian hospital . Main inclusion criterion neurological symptom suggestive LNB without obvious reason , one ) Cerebrospinal fluid pleocytosis ( &gt; 5 leukocytes/mm3 ) b ) intrathecal Bb antibody Production sign informed consent . Safety assessment trial : Comparison clinical outcome six month end treatment two treatment group . Subjective experience blood test include hematology biochemistry four week end treatment .</brief_summary>
	<brief_title>Six Versus Two Weeks Treatment With Doxycycline Lyme Neuroborreliosis</brief_title>
	<detailed_description />
	<mesh_term>Lyme Neuroborreliosis</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1 . Neurological symptom suggestive LNB without obvious reason one 1 . Cerebrospinal fluid pleocytosis ≥5 leukocytes pr mm3 2 . Intrathecal Bb antibody production 2 . Signed informed consent Age le 18 year Pregnancy , breastfeed Adverse reaction tetracycline Treatment cephalosporin , penicillin , tetracycline last 14 day Serious liver kidney disease contraindicate use doxycyline Lactose intolerance Need use medication contraindicate accord Summary Product Characteristics Investigational Medicinal Product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>